Regeneron injunction request in US antitrust case over cholesterol drug 'outlandish,' Amgen says
MLex Summary: Amgen told a US federal judge that the injunction Amgen seeks in a US antitrust case is “outlandish and contrary to any recognized principle of law.” Amgen argued that...To view the full article, register now.
Already a subscriber? Click here to view full article